ɬÀï·¬

Lipid News

Bacterial sphingolipids: Perhaps not as rare as we thought?

Eric A. Klein
By Eric A. Klein
Oct. 1, 2019

Among the ways cells adapt to changes in their environment, regulation of the lipidome is critical for maintaining cellular integrity. Species that lack temperature homeostasis adapt by modulating acyl chain saturation to resist changes in membrane fluidity. Bacteria such as Escherichia coli desaturate their fatty acids as temperatures decrease; the double bonds formed by acyl chain desaturation introduce kinks in the fatty acids that inhibit lipid packing and increase membrane fluidity to counteract the effects of lower temperature.

Gram-negative aquatic bacterium Caulobacter crescentusEric Klein’s lab showed that the Gram-negative aquatic bacterium Caulobacter crescentus synthesizes a novel glycosphingolipid when phosphates in its environment are limited.U.S. Department of Energy/Wikimedia Commons

Temperature is not the only environmental variable that necessitates membrane remodeling. In many settings, nutrient availability can vary widely. For example, nutrient levels in fresh-water lakes fluctuate with the seasons, and plant decomposition affects soil. In particular, oscillations in phosphate concentration can limit bacterial growth.

When phosphates are limited, the synthesis of membrane phospholipids becomes an obvious challenge. Studies have shown that alphaproteobacteria, such as and , adapt to phosphate starvation by increasing production of diacylglycerol-based glyceroglycolipids and ornithine lipids.

In our lab, that the Gram-negative aquatic bacterium Caulobacter crescentus responds to phosphate limitation by synthesizing a novel hexosyl-hexuronosyl-ceramide glycosphingolipid, or GSL. Ceramide-based GSLs are ubiquitous in eukaryotic organisms, but in bacteria they had been observed previously only in the Sphingomonadaceae family, where they function as a substitute for outer-membrane lipopolysaccharides, or LPS. Unlike Sphingomonas species, C. crescentus produces LPS even during phosphate starvation; in this organism, the GSLs appear to play a role in resistance to phage-mediated killing.

Now that we know that bacterial GSLs are not limited to just the Sphingomonadaceae, just how widespread are these lipid species? The honest answer is that we simply don’t know. While the lipidomes of many bacteria have been characterized, our findings in C. crescentus demonstrate that lipid abundance can vary with growth conditions. Indeed, previous characterizations in rich growth media did not identify GSLs in C. crescentus.

Another major challenge is that, unlike for eukaryotes, we do not know which enzymes are responsible for ceramide synthesis in prokaryotes. Only the enzyme that catalyzes the first step of ceramide synthesis, serine palmitoyltransferase, has clear homologues in bacteria as described in a . This implies that either (1) bacteria carry out the same synthetic chemistry as eukaryotes, but these enzymes diverged so long ago that the functionally equivalent proteins cannot be identified by sequence homology or (2) bacterial ceramide synthesis evolved independently using novel enzymes and/or synthetic pathways. If the genes required for ceramide synthesis are identified, researchers will be able to take a bioinformatic approach to finding additional species that might produce these lipids.

A growing body of work demonstrates that bacterially produced sphingolipids may play an important role in aspects of human health such as gut homeostasis and oral pathology. Uncovering the mechanism of prokaryotic ceramide synthesis will help determine how widespread these lipids are in bacteria and also may provide a novel route for pharmacological intervention.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Eric A. Klein
Eric A. Klein

Eric A. Klein is an assistant professor in the biology department and the Center for Computational and Integrative Biology at Rutgers University–Camden.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ɬÀï·¬ paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent ɬÀï·¬ paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.